Drug-induced liver disease: Primer for the primary care physician

Disease-a-Month

Volumn 60, Issue 2, 2014, Pages 55-104

  O'Donnell, James T ^a   Marks, Donald H ^a   Danese, Paul ^a   O'Donnell, James J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; CYTOCHROME P450; DICLOFENAC; ISONIAZID; MACROLIDE; METHOTREXATE; MICROSOME ENZYME; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; SULINDAC;

BILE DUCT INJURY; BUDD CHIARI SYNDROME; CHOLESTASIS; CHRONIC ACTIVE HEPATITIS; CLINICAL FEATURE; FATTY LIVER; FOOD AND DRUG ADMINISTRATION; FULMINANT HEPATIC FAILURE; GENERAL PRACTITIONER; HEPATITIS; HISTOPATHOLOGY; HUMAN; HYPERBILIRUBINEMIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; PURPURA; REVIEW; REYE SYNDROME; RISK FACTOR; SCLEROSING CHOLANGITIS; TOXIC HEPATITIS; VASCULAR DISEASE;

DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHYSICIANS, PRIMARY CARE; PRIMARY HEALTH CARE;

EID: 84893450785     PISSN: 00115029     EISSN: 15578194     Source Type: Journal    
DOI: 10.1016/j.disamonth.2013.11.002     Document Type: Review

References (83)

1. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002, 22:145-155.
2. Dossing M., Sonne J. Drug-induced hepatic disorders. Drug Saf 1993, 9:441-449.
3. MacLaren R. Hepatic and cholestatic diseases. Drug-Induced Diseases: Prevention, Detection, and Management 2005, 515-535. American Society of Health System Pharmacists, Bethesda, MD. J.E. Tisdale, D.A. Miller (Eds.).
4. Stricker B.H.C.H. Drug-Induced Hepatic Injury 1992, Elsevier, Amsterdam. 2nd ed.
5. Farrell G.C. Drug-induced acute hepatitis. Drug-Induced Liver Disease 1994, 247-299. Churchill Livingstone, Edinburgh. G.C. Farrell (Ed.).
6. Pessayre O., Larrey D., Biour M. Drug-induced liver injury. Oxford Textbook of Clinical Hepatology 1999, 1261-1315. Oxford University Press, Oxford. 2nd ed. J. Bircher, J.P. Benhamou, N. McIntyre, M. Rizzetto, J. Rodés (Eds.).
7. Zimmerman H.J. Drug-induced liver disease. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver 1999, 427-456. Lippincott Williams & Wilkins, Philadelphia. 2nd ed. H.J. Zimmerman (Ed.).
8. Larrey D. Drug-induced liver diseases. J Hepatol 2000, 32:77-88.
9. Navarro V.J., Senior J.R. Drug-related hepatotoxicity. N Engl J Med 2006, 354:731-737.
10. Biour M., Poupon R., Grange J.D., Chazouilleres O. Hépatotoxicité des medicaments. Gastroenterol Clin Biol 2000, 11:1052-1091.
11. Larrey D. Hepatotoxicity of herbal medicines. J Hepatol 1997, 26:47-51.
12. Schuppan D., Jia J.D., Brinkhaus B., Hahn E.G. Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology 1999, 30:1099-1104.
13. Seeff L.B., Lindsay K.L., Bacon B.R., Kresina T.F., Hoofnagle J.H. Complementary and alternative medicine in chronic liver disease. Hepatology 2001, 34:595-603.
14. Mackay I.R. Immune mechanisms and liver toxicity. Drug-Induced Hepatotoxicity 1996, 221-247. Springer, Berlin. R.G. Cameron, G. Feuer, F.A. de la Inglesia (Eds.).
15. Bernal W., Wendon J. Acute Liver Failure. N Engl J Med 2013, 369:2525-2534.
16. Lee W.M. Assessing causality in drug-induced liver injury. J Hepatol 2000, 33:1003-1005.
17. Larrey D. Hépatites médicamenteuses: aspects épidémiologiques, cliniques, diagnostiques, et physiopathologiques en 1995. Rev Med Int 1995, 16:752-758.
18. Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J Am Med Assoc 1998, 279:1200-1205.
19. Dossing M., Andreasen B.P. Drug-induced liver disease in Denmark. An analysis of 572 cases of hepatotoxicity reported to the Danish board of adverse reaction to drugs. Scand J Gastroenterol 1982, 17:205-211.
20. Bernuau J., Benhamou J.P. Fulminant and subfulminant liver failure. Oxford Textbook of Clinical Hepatology 1999, 1341-1372. Oxford University Press, Oxford. 2nd ed. J. Bircher, J.R. Benhamou, N. McIntyre, M. Rizzetto, J. Rodés (Eds.).
21. Jick H., Walker A.M., Porter J. Drug-induced liver disease. J Clin Pharmacol 1981, 21:359-364.
22. Hallas J., Gram L.F., Grodum E., et al. Drug related admissions to medical wards: a population based survey. Br J Clin Pharmacol 1992, 33:61-68.
23. Rubin E. Iatrogenic hepatic injury. Hum Pathol 1980, 11:312-331.
24. Pateria P., de Boer B., MacQuillan G. Liver abnormalities in drug and substance abusers. Best Pract Res Clin Gastroenterol 2013, 27(4):577-596.
25. Bunchorntavakul C., Reddy K.R. Acetaminophen-related hepatotoxicity. Clin Liver Dis 2013, 17(4):587-607.
26. Chalasani N., Björnsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010, 138(7):2246-2259.
27. Myers R.P., Shaheen A.A., Li B., Dean S., Quan H. Impact of liver disease, alcohol abuse, and unintentional ingestions on the outcomes of acetaminophen overdose. Clin Gastroenterol Hepatol 2008, 6(8):918-925.
28. Larson A.M., Polson J., Fontana R.J., Davern T.J., Lalani E., Hynan L.S., Reisch J.S., Schiødt F.V., Ostapowicz G., Shakil A.O., Lee W.M. Acute Liver Failure Study Group. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005, 42(6):1364-1372.
29. Mitchell J.R., Thorgeirsson U.P., Black M., et al. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther 1975, 18:70-79.
30. Ellard G.A., Mitchison D.A., Girling D.J., Nunn A.J., Fox W. The hepatic toxicity of isoniazid among rapid and slow acetylators of the drug. Am Rev Respir Dis 1978, 118:628-629.
31. Krähenbühl S. Mitochondria: important target for drug toxicity?. J Hepatol 2001, 34:334-336.
32. Kanel G.C., Korula J. Liver Biopsy Evaluation-Histologic Diagnosis and Clinical Correlations 2000, W.B. Saunders, Philadelphia.
33. Black M., Mitchell J.R., Zimmerman H.J., Ishak K.G., Epler G.R. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975, 69:289-302.
34. Chitturi S., Farrell G.C. Drug-induced cholestasis. Semin Gastrointest Dis 2001, 12:113-124.
35. Lewis J.H. Drug-induced liver disease. Med Clin North Am 2000, 84:1275-1311.
36. Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an international consensus meeting. Int J Clin Pharmacol Ther Toxicol 1990, 28:317-322.
37. Minton N.A., Henry J.A., Frankel R.J. Fatal paracetamol poisoning in an epileptic. Hum Toxicol 1988, 7:33-34.
38. Jaeschke H., Gores G.J., Cederbaum A.I., Hinson J.A., Pessayre D., Lemasters J.J. Mechanisms of hepatotoxicity. Toxicol Sci 2002, 65:166-176.
39. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231.
40. Marks D.H. Case report: drug toxicity leading to vanishing bile duct syndrome and cholestatic jaundice. Internet J Gastroenterol 2009, 8:p6.
41. Degott C., Feldmann G., Larrey D., et al. Drug-induced prolonged cholestasis in adults: a histological semi quantitative study demonstrating progressive ductopenia. Hepatology 1992, 15:244-251.
42. Prescott L.F. Liver damage with non-narcotic analgesics. Med Toxicol 1986, 1:44-56.
43. Boelsterli U.A., Zimmerman H.J., Kretz-Rommel A. Idiosyncratic liver toxicity of nonsteroidal anti-inflammatory drugs: molecular mechanisms and pathology. Crit Rev Toxicol 1995, 25:207-235.
44. Nuki G. Pain control and the use of non-steroidal analgesic anti-inflammatory drugs. Br Med Bull 1990, 46:262-278.
45. Tarazi E.M., Harter J.G., Zimmerman H.J., Ishak K.G., Eaton R.A. Sulindac-associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration. Gastroenterology 1993, 104:569-574.
46. Lee W.M. Drug induce hepatotoxicity. N Engl J Med 2003, 349:474-485.
47. Rapha Group Software, Inc. 1996.
48. Linden C.H., Rumack B.H. Acetaminophen overdose. Emerg Clin North Am 1984, 2:103-119.
49. Linden C.H., Rumack B.H. Acetaminophen poisoning. Emergency Medicine: A Comprehensive Study Guide 1992, 593-597. McGraw-Hill, New York. 3rd ed. J.E. Tintinalli, R.L. Krome, E. Ruiz (Eds.).
50. Reynolds J.E.F. Martindale: The Extra Pharmacopoeia 1989, 32. The Pharmaceutical Press, London. 29th ed.
51. Facts and Comparisons Drug Information 1986, Facts and Comparisons, St. Louis, MO, [Print].
52. Prescott L.F., Critchley J.A., Balali-Mood M., Pentland B. Effects of microsomal enzyme induction on paracetamol metabolism in man. Br J Clin Pharmacol 1981, 12:149-153.
53. Wallace R.J., Brown B.A., Griffith D.E. Drug intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis 1993, 16:215-221.
54. Brown B.A., Wallace R.J., Griffith D.E., Girard W. Clarithromycin-induced hepatotoxicity. Clin Infect Dis 1995, 20:1073-1074.
55. Shaheen N., Grimm I.S. Fulminant hepatic failure associated with clarithromycin. Am J Gastroenterol 1996, 91:394-395.
56. Hussar DA. They may call it an "express," but it is on the wrong track (Call for Rezulin Market Withdrawal). Editorial. Pharmacy Today. October 1999, American Pharmaceutical Association.
57. vanDooren-Greebe R.J., Kuijpers A.L., Buijs W.C., et al. The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients. Br J Dermatol 1996, 134:481-487.
58. Malatjalian D.A., Ross J.B., Williams C.N., Colwell S.J., Eastwood B.J. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol 1996, 10:369-375.
59. West S.G. Methotrexate hepatotoxicity. Rheum Dis Clin North Am 1997, 23:883-915.
60. Erickson A.R., Reddy V., Vogelgesang S.A., West S.G. Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthritis Rheum 1995, 38:1115-1119.
61. Tett S.E., Triggs E.J. Use of methotrexate in older patients. A risk-benefit assessment. Drugs Aging 1996, 9:458-471.
62. Kremer J.M., Alarcón G.S., Lightfoot R.W., et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994, 37:316-328.
63. Newman E.D., Scott D.W. The use of low-dose oral methotrexate in the treatment of polymyositis and dermatomyositis. J Clin Rheumatol 1995, 1:99-102.
64. Hakim A.J., Machin S.J., Isenberg D.A. Autoimmune thrombocytopenia in primary antiphospholipid syndrome and systemic lupus erythematosus: the response to splenectomy. Semin Arthritis Rheum 1998, 28:20-25.
65. Montilla Morales C., López Longo F.J., Moreno Zazo M., Monteagudo Sáez I., Moreno García A.C., Carreño Pérez L. Hypertransaminemia and methotrexate: not always a toxic effect?. Rev Clin Esp 1998, 198:822-824.
66. Kremer J.M., Furst D.E., Weinblatt M.E., Blotner S.D. Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. J Rheumatol 1996, 23:459-461.
67. Fuchs S., Simon Z., Brezis M. Fatal hepatic failure associated with ciprofloxacin. Lancet 1994, 343:738-739.
68. Grassmick B.K., Lehr V.T., Sundareson A.S. Fulminant hepatic failure possibly related to ciprofloxacin. Ann Pharmacother 1992, 26:636-639.
69. Samarasinghe D.A., Farrell G.C. Drug-induced liver disease. Current Hepatology 1994, 14:117-167.
70. Sheikh N.M., Philen R.M., Love L.A. Chaparral-associated hepatotoxicity. Arch Intern Med 1997, 157:913-919.
71. Boelesteri U.A., Zimmerman H.J., Kretz-Rommel A. Idiosyncratic liver toxicity of nonsteroidal anti-inflammatory drugs: molecular mechanisms and pathology. Crit Rev Toxicol 1995, 25:207-235.
72. Rumack B. Acetaminophen overdose in children and adolescents. Pediatr Clin North Am 1986, 33:691.
73. Rumack B. Acetaminophen overdose in young children. Am J Dis Child 1984, 138:428.
74. Watkins P.B., Kaplowitz N., Slattery J.T., et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. J Am Med Assoc 2006, 296(1):87-93.
75. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 2006, 44(suppl 1):S132-S139.
76. Heil EL, Townsend ML, Shipp K, Clarke A, Johnson MD. Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected Patients. AIDS Research and Treatment, vol. 2010, AIDS Research and Treatment. Article ID 856542.
77. Marks D.H. Evaluation of medical causation. Drug Injury: Liability, Analysis and Prevention 2012, L&J Publications, Tucson. 3rd ed. J.T. O'Donnell (Ed.).
78. Lurain N.S., Thompson K.D. Antiviral agents. Manual of Clinical Microbiology 2011, ASM Science, Washington DC. 10th ed. J. Versalovic, K.C. Carroll, G. Funke, J.H. Jorgensen, M.L. Landry, Warnock (Eds.).
79. 〈〉 Accessed 09.11.13. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5147a1.htm.
80. Moellering RC. Hepatotoxicity of antimicrobials: the trovafloxacin story. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada; 2000. Abstract 1880.
81. O'Donnell J.T. Liability, litigation, and lessons in new drug development (Chapter 13). Drug Injury: Liability, Analysis, and Prevention 2012, Lawyers & Judges Publishers, Tucson, AZ. 3rd ed. J.T. O'Donnell (Ed.).
82. Marks D.H., O'Donnell J.T. Drug induced liver disease (Chapter 13). Drug Injury: Liability, Analysis, and Prevention 2012, Lawyers & Judges Publishers, Tucson, AZ. 3rd ed. J.T. O'Donnell (Ed.).
83. 〈〉 Accessed 22.11.13. http://www.fda.gov/Food/RecallsOutbreaksEmergencies/Outbreaks/ucm370849.htm.